Safety and screening
Ibogaine safety centers on cardiac risk management. In IV ibogaine infusion — intravenous psychoactive ibogaine under physician supervision — patients undergo consult and screening, then receive a monitored IV infusion with continuous ECG/telemetry. Screening is not bureaucracy; it is the ethical center of a supervised path.
The risk you cannot market away
Deaths associated with ibogaine in non-medical and medical-adjacent settings have been reported, with cardiac mechanisms — particularly arrhythmias preceded by QT prolongation — frequently discussed. This page is the trust home for safety questions across condition pages and inquiry conversations on this site.
Evidence gap: Much of the best-known QTc literature (e.g., Knuijver et al., Addiction, 2021) observed oral ibogaine HCl; Cherian et al. (Nature Medicine, 2024) used oral ibogaine with IV magnesium. Those papers inform risk thinking but are not IV-psychoactive RCTs. True IV infusion does not erase risk — it raises the bar for monitoring during intravenous administration.
QTc prolongation in plain language
The QT interval on an ECG reflects ventricular recovery. Corrected for heart rate (QTc), excessive prolongation raises risk for torsades de pointes — a polymorphic ventricular tachycardia that can degenerate to fatal arrhythmia. Ibogaine pharmacology has been associated with hERG potassium channel effects that delay repolarization. Clinical observation confirms this is not theoretical only.
Landmark open-label cardiac observation (oral route)
Knuijver et al. (Addiction, 2021) studied oral ibogaine HCl in opioid-dependent patients. Reported findings included clinically relevant QTc prolongation, a substantial share of subjects reaching QTc >500 ms during observation, bradycardia and blood-pressure decreases, and severe transient ataxia. Absence of torsades in a small sample does not equal absence of risk.
Route label: These are oral-exposure findings. They still justify non-negotiable monitoring for IV psychoactive protocols, which change pharmacokinetics and must not be assumed safer without data.
Support IV electrolytes vs psychoactive IV ibogaine
Nausea, vomiting, poor intake, and prior substance use can deplete potassium and magnesium — electrolytes intertwined with cardiac repolarization. Medical programs emphasize baseline labs, repletion when indicated, IV access for ongoing correction, and avoiding hotel magnesium as a safety plan.
Magnesium coadministration in veteran-focused observational protocols is a support/coadministration story with oral ibogaine — not proof that psychoactive IV ibogaine is validated. See what infusion means.
Pre-infusion screening themes (educational, not a protocol)
- Full medication and supplement list (QT-prolonging agents, stimulants, opioids, alcohol, benzos)
- Personal/family history of sudden death, long QT, syncope, cardiomyopathy
- Baseline 12-lead ECG with QTc
- Electrolytes (K, Mg, Ca as indicated), renal/hepatic labs as indicated
- Substance-use timing (withdrawal state can itself stress physiology)
- Psychiatric risk assessment and observation plan
- Written confirmation of psychoactive route (IV) and monitoring duration
Contraindications and cautions (non-exhaustive)
Often discussed as high concern: congenital or acquired long QT; baseline QTc already markedly prolonged; decompensated heart failure, recent MI, unstable angina, serious arrhythmia history; uncorrected severe electrolyte derangement; combinations of multiple QT-prolonging drugs without a specialist plan.
Relative / contextual cautions: structural heart disease; severe liver disease affecting metabolism; unstable medical illness; inability to be continuously monitored. Physician judgment rules — this list is educational, not a clearance algorithm.
Being declined can protect you
A program that rarely says no may be optimizing enrollment over safety. Exclusion criteria are a feature of serious medicine. Prefer programs that describe emergency transfer plans, ACLS-capable staffing, and refund / medical-cancel policies when screening fails.
Further reading
Next step
Request a screening-first conversation
Screening comes before any treatment conversation — not after a sales pitch. Supervised IV ibogaine infusion inquiry is available provisionally in Mexico; not a U.S. FDA-approved clinic.